Frequency Therapeutics Future Growth
Future criteria checks 0/6
Frequency Therapeutics's earnings are forecast to decline at 4.7% per annum. EPS is expected to grow by 10.4% per annum.
Key information
-4.7%
Earnings growth rate
10.4%
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 26 Sep 2023 |
Recent future growth updates
Recent updates
Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?
Jan 01
Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?
Jan 19Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year
Aug 18Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?
Jul 31Frequency Therapeutics (FREQ) Investor Presentation - Slideshow
Jun 18Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout
Apr 21Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be
Apr 04We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn
Mar 15If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns
Jan 22Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?
Dec 27Frequency Therapeutics to host investor event in early January next year
Dec 18How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?
Dec 10Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 19Frequency Therapeutics EPS beats by $0.16, beats on revenue
Nov 16Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
Nov 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -57 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -44 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -50 | N/A | N/A | 2 |
| 9/30/2023 | N/A | -59 | -43 | -43 | N/A |
| 6/30/2023 | N/A | -67 | -50 | -50 | N/A |
| 3/31/2023 | N/A | -78 | -55 | -55 | N/A |
| 12/31/2022 | N/A | -82 | -58 | -58 | N/A |
| 9/30/2022 | N/A | -86 | -61 | -61 | N/A |
| 6/30/2022 | N/A | -91 | -64 | -64 | N/A |
| 3/31/2022 | 9 | -88 | -70 | -68 | N/A |
| 12/31/2021 | 14 | -85 | -79 | -76 | N/A |
| 9/30/2021 | 24 | -73 | -80 | -73 | N/A |
| 6/30/2021 | 35 | -54 | -77 | -69 | N/A |
| 3/31/2021 | 34 | -42 | -68 | -61 | N/A |
| 12/31/2020 | 37 | -27 | -52 | -45 | N/A |
| 9/30/2020 | 32 | -22 | -63 | -60 | N/A |
| 6/30/2020 | 45 | -18 | 23 | 25 | N/A |
| 3/31/2020 | 36 | -19 | 30 | 31 | N/A |
| 12/31/2019 | 29 | -20 | 33 | 34 | N/A |
| 9/30/2019 | 24 | -20 | 58 | 59 | N/A |
| 6/30/2019 | N/A | -23 | -20 | -19 | N/A |
| 3/31/2019 | N/A | -21 | -20 | -19 | N/A |
| 12/31/2018 | N/A | -19 | -17 | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FREQ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FREQ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FREQ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if FREQ's revenue is forecast to grow faster than the US market.
High Growth Revenue: FREQ is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FREQ's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/05 21:18 |
| End of Day Share Price | 2023/11/03 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Frequency Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Daniil Gataulin | Chardan Capital Markets, LLC |